Alderline Group
VC Fund
Alderline Group is a VC fund focused on Medical and Health Care. Freepoint Capital Group focuses on advancing healthcare innovation by investing in enterprises at the intersection of technology, data science, and life sciences. The company aims to enhance clinical efficacy, quality, and accessibility of care through strategic partnerships. With over 70 years of combined experience, Freepoint Capital Groupleverages its extensive network and expertise to drive operational excellence and value creation in the healthcare sector.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Alderline Group invests in
Stages Alderline Group invests in
Countries Alderline Group invests in
Investment Focus
Industry
- Medical 3 (75%)
- Health Care 3 (75%)
- Life Science 2 (50%)
- Biotechnology 2 (50%)
- Pharmaceutical 2 (50%)
Stage
- Series A 2 (50%)
- Series D 1 (25%)
- Series F 1 (25%)
Country
- United States 3 (75%)
- Israel 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Third Arc Bio
|
Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases. Its drug development engine delivers superior biologics optimized to create T-cell engagement by leveraging two technologies that power a pipeline of high-value therapeutics – a solid tumor synergy platform and an I&I platformthat offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. | $52M / Series A / Feb 04, 2026 | |
Parabilis Medicines
|
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M / Series F / Jan 08, 2026 | |
Bright Uro
|
Bright Uro is an early-stage medical technology company. It is building the next generation of diagnostic devices for Urology. Utilizing advanced hardware, software, and data science can unlock new data streams and offer actionable insight for clinicians. | $32M / Series A / Oct 31, 2024 | |
Orasis Pharmaceuticals
|
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, andeasy-to-use. | $68M / Series D / Oct 08, 2024 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alderline Group invest in?
Alderline Group invests primarily in Medical, Health Care and Life Science startups, most often at Series A and Series D stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alderline Group last invest?
The most recent investment recorded for Alderline Group closed in Feb 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
